Dynamic Technology Lab Private LTD Denali Therapeutics Inc. Transaction History

Dynamic Technology Lab Private LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$16.2 - $23.18 $70,308 - $100,601	4,340 Added 18.8%	27,429 $589,000
Q3 2023 Nov 14, 2023	BUY	$20.63 - $30.17 $476,326 - $696,595	23,089 New	23,089 $476,000
Q1 2023 May 12, 2023	BUY	$21.91 - $32.67 $250,277 - $373,189	11,423 New	11,423 $263,000
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $185,425 - $275,104	7,140 New	7,140 $219,000
Q1 2022 May 16, 2022	SELL	$29.0 - $47.27 $352,640 - $574,803	-12,160 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $517,894 - $669,043	12,160 New	12,160 $542,000
Q2 2021 Aug 13, 2021	SELL	$50.3 - $78.44 $330,471 - $515,350	-6,570 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$53.8 - $81.53 $353,466 - $535,652	6,570 New	6,570 $375,000
Q2 2019 Aug 14, 2019	SELL	$18.5 - $28.14 $316,424 - $481,306	-17,104 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$17.99 - $24.65 $307,700 - $421,613	17,104 New	17,104 $397,000
Q3 2018 Nov 14, 2018	SELL	$12.46 - $21.74 $169,269 - $295,337	-13,585 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$15.25 - $21.02 $207,171 - $285,556	13,585 New	13,585 $207,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $3.13B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.